APA (7th ed.) Citation

Derenzini, E., Gibb, A., Kwiatek, M., & Strati, P. (2025). Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Drug profile and expert opinion on the prevention and management of adverse events. Leukemia & Lymphoma, 66(11), 1990. https://doi.org/10.1080/10428194.2025.2520440

Chicago Style (17th ed.) Citation

Derenzini, Enrico, Adam Gibb, Michał Kwiatek, and Paolo Strati. "Loncastuximab Tesirine in Relapsed/refractory Diffuse Large B-cell Lymphoma: Drug Profile and Expert Opinion on the Prevention and Management of Adverse Events." Leukemia & Lymphoma 66, no. 11 (2025): 1990. https://doi.org/10.1080/10428194.2025.2520440.

MLA (9th ed.) Citation

Derenzini, Enrico, et al. "Loncastuximab Tesirine in Relapsed/refractory Diffuse Large B-cell Lymphoma: Drug Profile and Expert Opinion on the Prevention and Management of Adverse Events." Leukemia & Lymphoma, vol. 66, no. 11, 2025, p. 1990, https://doi.org/10.1080/10428194.2025.2520440.